MarketCap
Facebook
X
TelegramQuarterly report 2022-Q2
added 12-23-2023
Zymeworks Accounts Payables 2011-2026 | ZYME
Accounts payable — are the obligations of an organization to other legal entities or individuals that arise in cases when the company has acquired goods or services on deferred payment terms, has not paid taxes and fees, has wage arrears to employees, or has received loans and other liabilities. Accounts payable arise when an organization has already received some benefit but has not yet paid for it.Main types of accounts payable
| Type of liability | Example |
|---|---|
| To suppliers and contractors | Goods received but not yet paid for |
| Taxes and fees | VAT, income tax, etc., not paid on time |
| Salaries | Employee wages not paid |
| To budgets | Insurance contributions to funds not paid |
| To founders | Founders provided borrowed funds |
| To banks | Overdue loan payments |
| Other | Fines, penalties, forfeits, customer prepayments, etc. |
Impact on the company's financial performance
- Liquidity and solvency
Accounts payable are part of short-term liabilities, so they affect liquidity ratios - Financial stability
The higher the share of borrowed funds (including accounts payable), the lower the company's level of independence - Capital turnover
Moderate accounts payable can positively affect working capital by allowing the company to use “free” financing from suppliers (payment deferrals) - Risks and reputation
Large and especially overdue accounts payable may indicate financial difficulties. This can deter investors, partners, and lenders, and at a critical level of debt and lack of resources to repay it, bankruptcy proceedings may be initiated
Annual Accounts Payables Zymeworks
| 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|
| 5.17 M | 6.24 M | 5.35 M | 2.6 M | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 6.24 M | 2.6 M | 4.84 M |
Quarterly Accounts Payables Zymeworks
| 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | 14 M | 5.17 M | 5.05 M | 4.66 M | 4.88 M | 6.24 M | 6.24 M | 6.24 M | 6.24 M | 5.35 M | 5.35 M | 5.35 M | 5.35 M | 2.6 M | 2.6 M | 2.6 M | 2.6 M | 1.66 M | 1.66 M | 1.66 M | 1.66 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 14 M | 1.66 M | 4.63 M |
Accounts Payables of other stocks in the Biotechnology industry
| Issuer | Accounts Payables | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Adagene
ADAG
|
4.24 M | $ 2.19 | 7.88 % | $ 123 M |  China |
 |
Acorda Therapeutics
ACOR
|
13.4 M | - | -24.86 % | $ 820 K |  USA |
 |
BioXcel Therapeutics
BTAI
|
16 M | $ 1.83 | 0.83 % | $ 4.64 M | USA |
 |
AgeX Therapeutics
AGE
|
1.41 M | - | -10.17 % | $ 12.2 K | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
561 K | $ 4.23 | 1.68 % | $ 9.2 B |  Israel |
 |
Aeglea BioTherapeutics
AGLE
|
677 K | - | - | $ 1.01 B | USA |
 |
Amphastar Pharmaceuticals
AMPH
|
30.5 M | $ 26.09 | -0.21 % | $ 1.26 B | USA |
 |
Akero Therapeutics
AKRO
|
9.03 M | - | - | $ 3.67 B | USA |
 |
Coherus BioSciences
CHRS
|
35.2 M | $ 2.03 | 27.67 % | $ 191 M | USA |
 |
Aptose Biosciences
APTO
|
1.26 M | - | -45.71 % | $ 1.2 M |  Canada |
 |
Aravive
ARAV
|
8.76 M | - | -13.39 % | $ 1.45 M | USA |
 |
Athira Pharma
ATHA
|
319 K | - | - | $ 269 M | USA |
 |
Akouos
AKUS
|
1.28 M | - | 0.23 % | $ 488 M | USA |
 |
AVROBIO
AVRO
|
27 K | - | 1083.1 % | $ 745 M | USA |
 |
Applied Molecular Transport
AMTI
|
1.58 M | - | - | $ 10.1 M | USA |
 |
ARCA biopharma
ABIO
|
3.46 M | - | 1052.0 % | $ 415 M | USA |
 |
Aytu BioScience
AYTU
|
10.6 M | $ 2.72 | 0.37 % | $ 17.1 M | USA |
 |
Corcept Therapeutics Incorporated
CORT
|
15.4 M | $ 42.02 | 1.74 % | $ 4.34 B | USA |
 |
Acasti Pharma
ACST
|
601 K | - | 4.01 % | $ 150 M | Canada |
 |
Catalyst Pharmaceuticals
CPRX
|
16.6 M | $ 24.23 | -0.9 % | $ 2.87 B | USA |
 |
Arrowhead Pharmaceuticals
ARWR
|
17.7 M | $ 70.82 | 1.77 % | $ 9.47 B | USA |
 |
Brickell Biotech
BBI
|
406 K | - | -5.38 % | $ 6.06 M | USA |
 |
BeiGene, Ltd.
BGNE
|
405 M | - | 0.49 % | $ 251 B |  Cayman-islands |
|
Champions Oncology
CSBR
|
4.25 M | $ 6.9 | -0.43 % | $ 94.3 M | USA |
 |
Ayala Pharmaceuticals
AYLA
|
4.08 M | - | - | $ 7.46 M | Israel |
 |
Adaptimmune Therapeutics plc
ADAP
|
8.13 M | - | -15.15 % | $ 60.3 M |  Britain |
 |
Albireo Pharma
ALBO
|
6.52 M | - | -0.23 % | $ 916 M | USA |
 |
Acer Therapeutics
ACER
|
3.81 M | - | 2.71 % | $ 14 M | USA |
 |
Bellicum Pharmaceuticals
BLCM
|
486 K | - | -9.72 % | $ 5.89 M | USA |
 |
Alpine Immune Sciences
ALPN
|
4.29 M | - | - | $ 2.17 B | USA |
 |
AlloVir
ALVR
|
247 K | - | 4.14 % | $ 49.1 M | USA |
 |
Ampio Pharmaceuticals
AMPE
|
750 K | - | -11.43 % | $ 502 K | USA |
 |
Biogen
BIIB
|
424 M | $ 171.66 | -1.23 % | $ 25 B | USA |
 |
Bio-Path Holdings
BPTH
|
457 K | - | - | $ 100 K | USA |
 |
BioVie
BIVI
|
2.2 M | $ 1.26 | 0.79 % | $ 1.86 M | USA |
 |
Baudax Bio
BXRX
|
3.93 M | - | 0.59 % | $ 63 K | USA |